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Abstract: Vascular endothelial growth factor receptor (VEGFR)-1 exists in different forms, derived
from alternative splicing of the same gene. In addition to the transmembrane form, endothelial
cells produce a soluble VEGFR-1 (sVEGFR-1) isoform, whereas non-endothelial cells produce both
sVEGFR-1 and a different soluble molecule, known as soluble fms-like tyrosine kinase (sFlt)1-14.
By binding members of the vascular endothelial growth factor (VEGF) family, the soluble forms
reduce the amounts of VEGFs available for the interaction with their transmembrane receptors,
thereby negatively regulating VEGFR-mediated signaling. In agreement with this activity, high levels
of circulating sVEGFR-1 or sFlt1-14 are associated with different pathological conditions involving
vascular dysfunction. Moreover, sVEGFR-1 and sFlt1-14 have an additional role in angiogenesis: they
are deposited in the endothelial cell and pericyte extracellular matrix, and interact with cell membrane
components. Interaction of sVEGFR-1 with α5β1 integrin on endothelial cell membranes regulates
vessel growth, triggering a dynamic, pro-angiogenic phenotype. Interaction of sVEGFR-1/sFlt1-14
with cell membrane glycosphingolipids in lipid rafts controls kidney cell morphology and glomerular
barrier functions. These cell–matrix contacts represent attractive novel targets for pharmacological
intervention in addition to those addressing interactions between VEGFs and their receptors.
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1. Introduction
During embryo development, cells from mesoderm differentiate into pluripotent hemangioblasts,
and then into angioblasts and endothelial cells, in a process called vasculogenesis. Endothelial cells
assemble into a primary capillary plexus that forms new capillaries and vessels by angiogenesis, as part
of the development of a new mature vascular system.
Angiogenesis, defined as the growth of new vessels from existing ones, is a main feature of
embryonic development, where it is of utmost importance [1]. In fact, blocking embryonic angiogenesis
leads to impairment of development and death of the embryo at an early stage, due to the lack of
a functional vascular system able to supply nutrients and oxygen and efficiently remove metabolic
byproducts. In adult life, angiogenesis is limited to particular physiological cases, such as hair growth,
ovarian and endometrial cycles, and wound healing. On the other hand, angiogenesis is associated with
a number of pathologies in adults, where tumor-derived or inflammation-driven molecules impair the
existing tissue balance between angiogenic inhibitors and activators [2]. This imbalance augments the
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presence of angiogenic factors, to which endothelial cells respond by starting to migrate and proliferate
by sprouting angiogenesis. The newly forming vessel network is also augmented by non-sprouting
angiogenesis (intussusception), namely the division of a vessel in two by formation of a cellular septum
in the center, and undergoes a fine remodeling that gives rise to a novel vascular system [1].
Vascular endothelial growth factor receptor-1 (VEGFR-1), previously known as fms-like tyrosine
kinase (Flt-1) [3], is a membrane receptor for different members of the vascular endothelial growth factor
(VEGF) family. In particular, VEGFR-1 binds VEGF-A with high affinity, and is the only known tyrosine
kinase receptor for VEGF-B and placenta growth factor (PlGF) [4,5]. Initial gene knockout studies
showed that VEGFR-1 was essential for development and differentiation of the embryonic vasculature.
In fact, embryos in which VEGFR-1 has been knocked-out died in utero between day 8.5 and 9.0 [6].
The defect was later ascribed to an increased outgrowth of endothelial cells and angioblast commitment,
which inhibited a proper organization of the embryonal vascular network [7]. In the same work,
VEGFR-1 role in vasculogenesis and angiogenesis was ascribed to VEGF-A binding, which determined
both suppression of excessive angioblast development and hampering of VEGF-A-mediated signaling.
Indeed, VEGFR-1 had been previously proposed to act as a “VEGF-sink”, regulating the amount
of VEGF-A available for vascular development through interaction with the other tyrosine kinase
receptors VEGFR-2 or VEGFR-3 [8]. In agreement with this hypothesis, mice carrying a homozygous
deletion of VEGFR-1 intracellular kinase domain showed correct development of blood vessels [8].
This result indicated that VEGFR-1 had a primary role in embryonic angiogenesis, independent of its
tyrosine kinase activity and restricted to its extracellular region. Actually, a differentially spliced form of
VEGFR-1 mRNA encoding a soluble receptor variant (sVEGFR-1) was isolated from cultured endothelial
cells. sVEGFR-1 comprises the 656 N-terminal residues of the receptor, followed by a specific 30 amino
acid tail at its C-terminus. This form is proposed to function as a modulator of VEGF-A-dependent
signaling, by forming non-signaling complexes with VEGFR-2 [9]. sVEGFR-1 has been later isolated
from different cell lines and demonstrated to act as a naturally-produced VEGF antagonist that inhibits
the mitogenic effects of VEGF-family growth factors by functioning as a dominant-negative trapping
protein [10]. In fact, addition of sVEGFR-1 can partially rescue the phenotype of VEGFR-1 knockout
mice, reducing the levels of VEGFR-2 tyrosine phosphorylation [11]. A second soluble form of VEGFR-1
has been then isolated, generated by alternative splicing downstream of exon 14 and polyadenylation
within an Alu element [12,13]. This soluble VEGFR-1, currently named sFlt1-14 or sFlt1-e15a, encodes a
C-terminal variant with a polyserine tail, and is produced by non-endothelial cells, such as epithelial,
dendritic cells, monocytes/macrophages, and vascular smooth muscle cells. An additional soluble
form of VEGFR-1 is generated by proteolytic cleavage of the transmembrane protein in the extracellular
portion, adjacent to the transmembrane domain [14]. These latter soluble isoforms have been shown
to act as VEGF antagonists as well. Altogether, studies with both animal models and cultured cells
support the concept that the main function of soluble VEGFR-1 isoforms, as well as the membrane one,
is negative regulation of VEGF signaling (Figure 1) [15].
In recent years, VEGF-B and PlGF signaling through transmembrane VEGFR-1 has been clearly
correlated with pathological angiogenesis in adults, and both growth factors have been recognized as
angiogenic factors, even in the absence of VEGF-A [16,17]. Thus, transmembrane VEGFR-1 transmits a
pro-angiogenic signal, and has a function besides that of VEGF-A sequestration or receptor antagonism
through dimerization [15]. Additionally, high levels of sVEGFR-1 or sFlt1-14 are found in pathological
conditions involved in vascular dysfunction, as discussed below. These observations restrict the
hypothesis that VEGFR-1 acts as a VEGF-sink/transmembrane receptor inhibitor to soluble VEGFR-1
isoforms only. Nevertheless, there are still unanswered questions about the assumption that soluble
VEGFR-1 isoforms have an exclusively negative role. It is relevant to note that the knockout model in
which only the tyrosine kinase domain was deleted [8] had the ability to produce both a transmembrane
form of VEGFR-1 without the intracellular domain, and the soluble forms sVEGFR-1 and sFlt1-14.
Therefore, the normal mouse phenotype could be ascribed to one of the following: formation of
inactive dimers with transmembrane receptors; interaction of soluble isoforms with VEGF-A; and/or
Int. J. Mol. Sci. 2018, 19, 1306 3 of 16
interaction of soluble isoforms with other molecules. A later mouse model was generated that
lacked both VEGFR-1 tyrosine kinase and transmembrane domain, resulting in the production of
soluble isoforms only [18]. About one-half of these mice died as embryos with abnormal blood vessel
formation, indicating that the presence of VEGFR-1 extracellular region anchored to the membrane
by the transmembrane domain was required to efficiently inhibit VEGF-A pro-angiogenic action.
Since VEGF-A binding region is present in the soluble isoforms as well, the highest inhibition of
VEGF-A signaling by the transmembrane form can be ascribed, at least in part, to a greater ability
to heterodimerize with VEGFR-2, thus reducing VEGF-A signaling mediated by the latter receptor.
In agreement with this hypothesis, the same mouse model produced in a different genetic background,
and expressing higher VEGFR-2 levels than the previous strain, led to the survival of most animals [18].
This suggests that increased amounts of VEGFR-2 can compensate for a putatively reduced activity
of the soluble forms as VEGF inhibitors. However, it could not be ruled out that other differences
between the two mouse strains (e.g., in factors involved in cell-to-matrix interactions) contributed to a
reversion of the mouse phenotype back to normal.
Figure 1. Anti-angiogenic roles of soluble vascular endothelial growth factor receptor (VEGFR)-1
VEGFR-1 isoforms. Soluble VEGFR-1 isoforms, either sVEGFR-1 or soluble fms-like tyrosine kinase
(sFlt)1-14, act as “VEGF sinks”. By binding members of the VEGF family, they decrease the amount
of growth factors available to interact with the transmembrane tyrosine kinase receptors. In addition,
soluble receptor isoforms can reduce VEGF signal transduction by binding to transmembrane
receptor monomers and blocking formation of signaling competent receptor homodimers. Receptor
heterodimers can also be inhibited by soluble isoforms, thus blocking the signaling of VEGF-A/placenta
growth factor (PlGF) or VEGF-A/VEGF-B heterodimers. Interactions that lead to and hamper
angiogenesis are indicated by green and red arrows/lines, respectively. The dashed arrow indicates
the limited pro-angiogenic activity of receptor heterodimers.
2. Structure of the Soluble Forms of VEGFR-1
Eight VEGFR-1 isoforms are present in the UniProt database [19] at the time of writing.
The aforementioned transmembrane VEGFR-1, sVEGFR-1, and sFlt1-14 correspond to isoforms 1,
2, and 3, respectively. Isoform 4 is an additional extracellular soluble protein, shorter than sFlt1-14
and sVEGFR-1 (it encompasses the five N-terminal immunoglobulin (Ig)-like domains, D1–D5) and
produced by proteolytic cleavage. Isoforms 5 to 8 map in the intracellular region of the receptor.
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Isoform 5 comprises the whole tyrosine kinase domain, whereas isoforms 6, 7, and 8 are truncated
variants missing different N-terminal regions of the tyrosine kinase domain. The biological significance
of isoforms 4 to 8 is still unclear.
High resolution three-dimensional (3D) structures of the second VEGFR-1 Ig-like domain (D2)
have been determined by X-ray crystallography and are available from the Protein Data Bank (PDB,
www.rcsb.org) [20]. In all these structures, D2 is in complex with one of its growth factor ligands:
VEGF-A (PDB ID: 1FLT, Resolution: 1.7 Å) [21]; VEGF-B (PDB ID: 2XAC, Resolution: 2.71 Å) [22]; and
PlGF (PDB ID: 1RV6, Resolution: 2.45 Å) [23]. More recently, the three-dimensional (3D) structure of the
almost complete VEGFR-1 extracellular region has been determined by employing different techniques,
including X-ray crystallography, single-particle electron microscopy, and molecular modeling (PDB ID:
5T89, Resolution: 4 Å) [24] (Figure 2). The structure comprises the six N-terminal Ig-like domains
D1–D6 in complex with VEGF-A, and is the largest structure of one member of the VEGFR family
reported to date.
Coordinates of VEGFR-1 Ig-like domain 7 (D7) are not available from the PDB; however,
a molecular model of this domain can be built using the experimentally determined structure of the
homologous VEGFR-2 D7 (PDB ID: 3KVQ, Resolution: 2.7 Å) as a template. As far as the C-terminal
regions of soluble VEGFR-1 isoforms are concerned, the specific 30 residues C-terminal tail of sVEGFR-1
is predicted to be disordered by PsiPred [25] (Figure 2). In the case of sFlt-1, the region following D6
is likely to be disordered as well. In fact, of the seven β-strands that form the two β-sheets packed
together in Ig-like domains, three are lost due to the replacement of the 706–733 region by a low
complexity sequence (20 out of 28 residues are serine), and another one is missing due to the absence
of residues 734–750 (Figure 2).
Figure 2. VEGFR-1 structures. Top: Soluble isoforms sVEGFR-1 (left) and sFlt1-14 (right) are shown
by ribbon representation. The 3D structure of Ig-like domains 1–6 (residues 1–654), common to both
isoforms, has been experimentally determined in complex with VEGF-A (PDB ID: 5T89, Resolution:
4 Å). VEGF monomers are orange and yellow. VEGFR-1 Ig-like domains 1, 3 and 5 are light green;
Ig-like domains 2, 4 and 6 are dark green; residues 657–705 of sFlt-1, whose sequence is identical
to transmembrane VEGFR-1 (isoform 1) are light green; the 30 residues C-terminal tail of sVEGFR-1
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(657–687) and residues 706–733 of sFlt-1, whose sequence differs from isoform 1 are red. The C-terminal
regions of sVEGFR-1 and sFlt1-14 have been modeled by homology using the structure of VEGFR-2
domain 7 (PDB ID: 3KVQ, Resolution: 2.7 Å) as a template, using the molecular graphics program
InsightII (Accelrys Software Inc., [26]). However, both these regions are likely to be, at least in the
red-colored part, disordered (see text). Bottom: Domain architecture of VEGFR-1 isoforms. VEGFR-1
is color coded as follows: N-terminal signal sequence, grey; Ig-like domains 1, 3, 5 and 7, light green;
Ig-like domains 2, 4, and 6, dark green; transmembrane helix, black; tyrosine kinase domain, blue;
disordered regions, striped. Isoform sequences that differ from transmembrane VEGFR-1 are red.
Boundaries of Ig-like domains 1–6 are defined according to the experimental structure. All the other
regions are defined based on a combination of programs for domain assignment (i.e., SMART [27],
Pfam [28], Superfamily [29]) and transmembrane helices (i.e., TMHMM [30]) or secondary structure
and disordered region predictions (i.e., PsiPred [25]). The length of each segment in the picture is
proportional to the number of residues comprised in each domain or region.
Analysis of the aforementioned structures allowed VEGFR-1 residues involved in the following
interactions to be identified: D2 residues interacting with VEGF-A, VEGF-B, or PlGF; D3 residues
interacting with VEGF-A; D4 and D5 residues involved in homotypic interactions between receptor
monomers, which occur downstream the growth factor binding region (Table 1). By superimposing
the structure of the D2 domain in complex with VEGF-B or PlGF to the D2 domain in the D1–D6
structure, D3 residues interacting with VEGF-B and PlGF could be inferred (Table 1). Finally, homotypic
interactions involving D7 domains, which are not present in the structures, were inferred from a
homology model built using as template the 3D structure of the homologous VEGFR-2 domain
(PDB ID: 3KVQ, Resolution: 2.7 Å) [31] (Table 1).
Table 1. VEGFR-1 residues involved in interaction with ligands or dimer formation.
PDB ID: 1FLT PDB ID: 2XAC PDB ID: 1RV6
VEGFR-1 D2 VEGF-A VEGFR-1 D2 VEGF-B VEGFR-1 D2 PlGF
142 I 17 F 141 E 16 S 140 S 25 F
143 P 18 M 142 I 17 W 141 E 26 Q
145 I 21 Y 143 P 21 Y 142 I 29 W
147 H 22 Q 145 I 22 T 143 P 30 G
171 K 25 Y 172 F 48 V 145 I 33 Y
172 F 46 I 199 Y 62 P 171 K 71 D
173 P 48 K 202 I 63 D 172 F 74 L
199 Y 63 D 203 G 66 L 173 P 89 L
204 L 65 G 204 L 79 Q 199 Y 91 I
221 L 66 L 221 L 81 L 203 G 97 P
223 H 81 M 224 R 88 S 204 L 99 Y
224 R 83 I 89 Q 219 N 114 P
225 Q 86 H 90 L 221 L
89 Q 105 P 223 H
91 I 224 R
105 R
106 P
PDB ID: 5T89 PDB ID: 5T89 PDB ID: 5T89 Homology Model
VEGFR-1 D3 VEGF-A VEGFR-1 D4 VEGFR-1 D4 VEGFR-1 D5 VEGFR-1 D5 VEGFR-1 D7 VEGFR-1 D7
226 T 34 D 351 R 351 R 382 R 675 S 675 S
227 N 36 F 379 K 379 K 394 D 676 S 676 S
258 L 40 P 380 S 380 S 429 Q 429 Q 677 S 677 S
259 N 41 D 381 A 381 A 431 Y 431 Y 704 E 704 E
260 T 43 I 382 R 382 R 432 E 432 E 705 P 705 P
261 R 44 E 393 K 393 K 433 K 433 K 706 G 706 G
262 V 45 Y 394 D 434 A 434 A 707 I 707 I
263 Q 46 I 435 V 435 V 708 I 708 I
264 M 63 D 436 S 436 S 717 F 717 F
277 S 64 E 437 S 437 S 719 E 719 E
278 V 65 G 438 F 438 F 720 R 720 R
279 R 84 K 439 P 439 P 722 T 722 T
280 R 85 P 451 I 451 I 725 D 725 D
282 I 86 H 453 T 453 T
284 Q 107 K 455 T 455 T
287 S 108 K 508 R 508 R
290 N 510 A 510 A
292 F 512 I 512 I
315 S 513 E 513 E
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Table 1. Cont.
PDB ID: 5T89 PDB ID: 5T89 PDB ID: 5T89 Homology Model
VEGFR-1 D3 VEGF-A VEGFR-1 D4 VEGFR-1 D4 VEGFR-1 D5 VEGFR-1 D5 VEGFR-1 D7 VEGFR-1 D7
316 G 517 K 517 K
317 P 519 A 519 A
521 T 521 T
VEGFR-1 residues reported in the table have at least one atom within a specific distance from at least one atom of
the indicated ligand. Selected thresholds were: 4.0 Å, in the case of the experimental structures of VEGFR-1 D2 in
complex with VEGF-A (PDB ID: 1FLT), VEGF-B (PDB ID: 2XAC), and PlGF (PDB ID: 1RV6), which have been solved
with resolution <2.8 Å; and 5.0 Å in the case of the experimental structure of VEGFR-1 D1-D6 (PDB IDs: 5T89),
which has been solved with resolution = 4.0 Å, and of the molecular model built by homology for the D7 dimer,
using as a template the 3D structure of VEGFR-2 D7-D7 dimer (PDB ID: 3KVQ). The latter threshold was chosen to
take into account possible errors in atom positioning due to the low resolution of the structure and inherent the
modeling procedure, respectively.
Knowledge of VEGFR-1 residues involved in essential interactions is a fundamental requirement
to rationally design molecules able to modulate angiogenesis and other biological functions mediated
by VEGFR-1 (see below). Indeed, several peptides mapping on the surface of VEGFR-1 D2 structure
were designed and shown to be endowed with pro- or anti-angiogenic activity, which was exerted by
mimicking or interfering with VEGFR-1 interactions [32–34].
3. Expression of Soluble Forms of VEGFR-1
The molecular mechanisms regulating alternative splicing process that gives raise to different soluble
forms of VEGFR-1 have been investigated. Differential splicing involves cis-regulatory elements in the
sVEGFR-1 mRNA, and has a major processing site in intron 13 [35]. While expression of transmembrane
VEGFR-1 and VEGF-A are increased by hypoxia [36,37], it is not clear whether sVEGFR-1 expression
is downregulated or upregulated by reduced oxygen concentration. In endothelial cells, sVEGFR-1
was reported to be downregulated by hypoxia through a mechanism that did not directly involve the
hypoxia-inducible factor (HIF)-1α [38]. On the other hand, hypoxia augments the amount of sVEGFR-1
produced by macrophages/monocytes after exposure to granulocyte-macrophage colony-stimulating
factor (GM-CSF), and this induction is dependent on HIF-2α with no contribution by HIF-1α [39].
Another study indicated that hypoxic conditions increase secretion of sFlt1-14 by a signaling pathway
that comprises activation of the growth arrest and DNA damage-inducible 45a (Gadd45a) factor and
p38 phosphorylation [40]. At variance with sVEGFR-1, which has been detected in most tissues,
sFlt1-14 is mainly produced in the placenta by cytotrophoblasts [41]. In this cell type, exposure to
hypoxia increases both sFlt1-14 and sVEGFR-1 mRNA, probably through stabilization of HIF-1α
protein [41]. Other drugs inhibit sFlt1-14 production by cytotrophoblasts using various pathways.
Ouabain, a cardiac glycoside, downregulates sFlt1-14 production through a HIF1α/heat-shock protein
27 (HSP27) pathway [42]. Aspirin decreases sFlt1-14 expression by inhibition of cyclooxygenase
1 [43] whereas metformin reduces sFlt1-14 secretion possibly by inhibiting the mitochondrial electron
transport chain [44]. Hydroxylases or demethylases can also influence sVEGFR-1/sFlt1-14 expression.
In fact, Jumonji domain-containing protein 6 regulates VEGFR-1 mRNA splicing by interacting with
and hydroxylating splicing factor U2AF65. Since this hydroxylating reaction depends on oxygen
concentration, hypoxia results in augmented sVEGFR-1/sFlt1-14 levels [45]. Differential methylation
has been found in a CpG island of VEGFR-1 promoter region in smoker’s lung macrophages compared
to cells from non-smoking individuals [46]. This results in increased levels of all three VEGFR-1
isoforms, i.e., the transmembrane, sVEGFR-1, and sFlt1-14, with sFlt1-14 being the most upregulated.
Treatment with phorbol myristic acid, an activator of protein kinase C, increases the abundance of
sVEGFR-1 mRNA and protein in endothelial cells [35]. Importantly, VEGF-A itself can stimulate the
expression of sVEGFR-1 by activating VEGFR-2 and protein kinase C [14].
Besides GM-CSF-mediated induction of sVEGFR-1 in human monocytes [47], at least two
other cytokines, interleukin-4 in macrophages and interleukin-6 in endothelial cells, increase
sVEGFR-1/sFlt1-14 secretion [38,48].
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In contrast with what happens for VEGF-A expression, a peptide that mimics the mRNA
regulatory protein AUF1/heterogeneous nuclear ribonucleoprotein (hnRNP) D stimulates soluble
VEGFR-1 isoform expression in macrophages [49]. In a similar way, and different from VEGF-A
induction, mechanical forces downregulate sVEGFR-1 expression by human chondrocytes [50].
In summary, soluble receptor isoforms and their ligands often appear to be inversely regulated.
As far as post-translation modifications are concerned, it should be considered that VEGFR-1
soluble forms are highly glycosylated, and inhibition of glycosylation, as well as of intracellular
trafficking, reduces secretion of these forms [12]. Soluble VEGFR-1 isoforms are also heparin
binding proteins, and they are stored in the vessel walls or in the placenta through heparin binding.
Both heparin and heparanase treatment release soluble isoforms from their storage matrix and release
them into circulation [51]. Thus, heparanase inhibition could be an alternative therapeutic target in
pathologies, where high amounts of soluble isoforms are present in the patient blood.
4. sVEGFR-1 and Vessel Sprouting
Sprouting angiogenesis consists of migration of endothelial cells from a parental vessel to give
rise to new vascular structures. Endothelial cells send out filopodia and migrate away from the parent
vessel without breaking contact with other endothelial cells, so that the sprout comprises several cells.
Moreover, endothelial cell division takes place, at the same time, behind the sprout leading tip [52].
Sprouting angiogenesis is modulated by different angiogenic factors mainly belonging to the VEGF,
platelet-derived growth factor (PDGF), and angiopoietin families [53].
A confocal time-lapse imaging study of VEGFR-1 knockout embryonic stem cells revealed
that sVEGFR-1 is important in modulating endothelial cell migration and vascular sprouting
during development [54]. The proposed mechanism is based on the production of sVEGFR-1 by
endothelial cells during vessel morphogenesis, and the formation of a VEGF-A gradient through
sVEGFR-1/VEGF-A interaction, which sequesters VEGF-A and locally inactivates VEGFR-2 signaling.
Endothelial cells derived from VEGFR-1 knockout embryonic stem cells have an increased mitotic
index, and defects in sprouting and branch formation [54,55]. This phenotype could be rescued by
reintroducing either transmembrane VEGFR-1 or sVEGFR-1; however, only sVEGFR-1 mends the
branching morphogenesis defect [56]. Therefore, sVEGFR-1 has been proposed to act as a guidance
molecule in vessel sprouting. By inactivating VEGF-A at either side of the sprout, sVEGFR-1 provides a
VEGF-A-rich corridor for the emerging vessel, maintaining it in the proper direction [56]. Interestingly,
vessel morphogenetic defects of VEGFR-1 knockout embryonic stem cells could be rescued through
inactivation of the Notch pathway, which is also activated by VEGF-A [57].
5. Soluble Forms of VEGFR-1 in Human Pathologies
Besides their role in tumor development and progression, which have been described
elsewhere [58,59], soluble VEGFR-1 isoforms have been related with different pathological conditions.
In 2006, the group of J. Ambati described, for the first time, the involvement of sVEGFR-1 in preserving
cornea avascularity through specific inhibition of VEGF-A [60]. Other works demonstrated that the
avascular privilege of retina photoreceptor layer depends on sVEGFR-1-mediated inactivation of
VEGF-A, as well. Reduced sVEGFR-1 expression was observed in patients suffering from age-related
macular degeneration, where retina angiomatous proliferation and choroidal neovascularization
are present [61]. Interestingly, reduced serum sVEGFR-1 occurred in patients with neovascular
age-related macular degeneration, with respect to earlier manifestations of the same pathology or
healthy individuals [62]. During the wound healing process, sVEGFR-1 levels in wound fluid are
initially low, similar to serum level; they increase during granulation tissue formation, and decrease
again at wound closure. However, in the fluid of chronic non-healing wounds, higher amounts
of sVEGFR-1 are present, and contribute to sustaining chronic ulceration [63]. Soluble VEGFR-1
isoforms have been found in the blood of pregnant women, but not in nonpregnant women and
men [64], and excess circulating soluble receptors contribute to the pathogenesis of the pregnancy
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disorder pre-eclampsia [65,66]. It is not clear which one of the two isoforms is involved, but a main
role is surely played by sFlt1-14, because it is selectively expressed in the placenta, and could be
considered as a placenta-specific protein [41]. Increased sFlt1-14 produced by the placenta sequesters
VEGF-A and PlGF, causing generalized endothelial dysfunction and altered neutrophil activation and
migration [67]. This results in the clinical features of pre-eclampsia, such as hypertension, proteinuria,
and glomerular endotheliosis [66]. It is now well established that increased circulating levels of
sFlt1-14 [68] and, even more, of the sFlt1-14/PlGF ratio [69], can be used to predict pre-eclampsia
development. Occurrence of hypertension in pre-eclampsia patients could be mediated by sFlt1-14
inhibition of VEGF-A and consequent reduced levels of nitric oxide and augmented amount of
endothelin-1, a potent vasoconstrictor [70]. sVEGFR-1 has been linked to endothelial cell function
in the kidney. Renal glomerular microvasculature is particular susceptible to local availability of
VEGF-A [71]. Plasma levels of sVEGFR-1 are higher in patients with chronic kidney disease, and
correlate with cardiovascular morbidity and heart failure [72,73]. Finally, soluble VEGFR-1 isoforms
have been linked to different states of inflammation. Increasing levels of sVEGFR-1 are present in
the blood of patients with sepsis, and may represent a potential new marker of disease severity [74].
Augmented plasma VEGF-A and sVEGFR-1 are present in liver cirrhosis patients compared to healthy
individuals [75], and serum levels of sVEGFR-1 represent a predictor of endothelial dysfunction and
activation of coagulation in acute pancreatitis [76]. Monocyte activation is important for a proper
immune response. Monocytes are able to bind immunoglobulins on target cells by their Fc-γ receptor.
This interaction stimulates monocytes to release pro-inflammatory cytokines, and initiate phagocytosis
and antibody-mediated cellular cytotoxicity. Interestingly, immunoglobulin-Fc-γ receptor engagement
also stimulates monocytes to secrete soluble VEGFR-1 isoforms [77]. The secreted isoforms, by blocking
VEGF-A signaling, contribute to reducing inflammatory angiogenesis, as well as interstitial pressure
and edema.
Regarding atherosclerosis, no clear data are available at present. On the one hand, reduced
levels of sVEGFR-1 and higher PlGF/sVEGFR-1 ratio are associated with accelerated progression of
atherosclerosis in patients suffering from renal dysfunction and in an experimental animal model [78].
On the other hand, high levels of sVEGFR-1 in hypertensive patients are an indicator of the progression
of carotid intima-media thickness, a marker of atherosclerosis [79]. Surely, additional studies are
required to fully understand the role and reveal the molecular mechanism of action of sVEGFR-1 and
sFlt1-14 in most pathologies.
6. Soluble VEGFR-1 Isoforms in the Extracellular Matrix
In the light of observation that not all the biological effects of sVEGFR-1 could be ascribed to
the regulation of VEGF signaling, we decided to investigate sVEGFR-1 location in the endothelial
cell microenvironment. In 2003, we showed, for the first time, that sVEGFR-1 is deposited by
cultured endothelial cells in the extracellular matrix, where it determines endothelial cell adhesion and
migration [80]. This activity is mediated by sVEGFR-1 interaction with α5β1 integrin, which is highly
involved in angiogenesis. In fact, antagonists of α5β1 integrin inhibit tumor vascularization [81],
and α5 subunit knockout is associated with reduced formation of vessel structures [82], and with
vascular and cardiac defects [83]. sVEGFR-1 interaction with α5β1 integrin is independent of the
presence of fibronectin or other matrix proteins that interact with integrins through an RGD sequence
motif. Additionally, neither VEGF-A or PlGF mediate sVEGFR-1 binding to α5β1 integrin. Notably,
endothelial cells spread weakly on sVEGFR-1-coated plates, displaying a cytoskeleton organization
different from that stimulated by adhesion on fibronectin [80]. To elucidate the molecular determinants
of sVEGFR-1/integrin interaction, we initially identified receptor D2 as a main site of interaction.
Subsequently, we isolated a seven-amino acid-long peptide mapping on this domain (peptide 12)
which efficiently inhibits sVEGFR-1 interaction with α5β1 integrin [84]. Moreover, peptide 12
supports, by itself, α5β1 integrin-mediated endothelial cell adhesion, migration, and vessel formation,
both in vitro and in vivo [84]. Following fibronectin binding, α5β1 integrin initiates a signal that
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leads to phosphorylation of the focal adhesion kinase (FAK) and of the adaptor Src-homology 2
domain-containing (Shc) protein [85]. Interestingly, peptide 12 interaction with α5β1 integrin does not
activate the FAK pathway, and induces only slight phosphorylation of Shc [84]. Further work from
our group revealed that sVEGFR-1, as well as peptide 12 interaction with α5β1 integrin, produces
a dynamic, motile phenotype in endothelial cells by activation of different molecular pathways.
After endothelial cell adhesion on sVEGFR-1, VEGFR-2 and/or α5β1 integrin initiate a signal that
leads to activation of protein kinase C alpha (PKCα) and its substrates adducin, myristoylated
alanine-rich protein kinase C substrate (MARCKS), and radixin [86]. Phosphorylation reduces adducin
activity, thus contributing to delaying focal adhesion assembly. Formation of focal adhesion is not
stimulated by FAK phosphorylation either, as sVEGFR-1 binding to α5β1 integrin did not initiate FAK
signaling [86]. MARCKS protein levels are increased after adhesion to matrix sVEGFR-1, but MARCKS
is not efficiently phosphorylated. Non-phosphorylated protein accumulates into structures, called
dynamic adhesions [87], contributing to stabilizing these structures and prompting cell movements [88].
Both α5β1 integrin and VEGFR-2 are known to regulate cell adhesion and migration through the Rho
family GTPases [89]. Only GTPase Rho family GTPase Rac1 is activated in cells adherent to sVEGFR-1,
probably by VEGFR-2 stimulation, since a FAK-mediated switch is absent. However, Rac1 activation
persists in time. Continual activation is due to binding to the heterotrimeric G protein α13 (Gα13) that
forms a complex with and induces a conformational change of radixin. This, in turn, stimulates Rac1.
Moreover, radixin phosphorylates calcium/calmodulin-dependent protein kinase II (CaMKII) [86]
(Figure 3).
Figure 3. Molecular signals of motility are activated by endothelial cell adhesion to matrix sVEGFR-1
through α5β1 integrin. Protein kinase C alpha (PKCα) phosphorylation by VEGFR-2 and/or α5β1
integrin (arrows) modulates both expression and phosphorylation (dotted arrow) of its substrates
adducin, myristoylated alanine-rich protein kinase C substrate (MARCKS), and radixin (RDX) (see text).
VEGFR-2 starts a signaling loop that involves the Rho family GTPase Rac1 and the heterotrimeric G
protein α13 (Gα13), and is sustained (red arrow) by the activation of radixin, which also phosphorylates
the calcium/calmodulin-dependent protein kinase II (CaMKII). Cell adhesion to matrix sVEGFR-1 does
not activate the focal adhesion kinase (FAK) signaling (cross and crossed arrows). As a consequence,
focal adhesion formation is blocked (bars). MARCKS expression is increased, and non-phosphorylated
MARCKS accumulates into and stabilizes dynamic adhesions (black arrow). Thus, endothelial cells
acquire a highly motile phenotype that allows them to initiate new vessel formation (thick black arrow).
The resulting endothelial cell phenotype is highly mobile, allowing sprouting angiogenesis and
formation of new vessels [86].
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In 2012, the group of S. E. Quaggin found that kidney podocytes produced soluble VEGFR-1
isoforms, and that selective deletion of VEGFR-1 highly affected cytoskeletal reorganization and
podocyte morphology, leading to development of proteinuria [90]. Reintroduction of VEGFR-1
extracellular domain, i.e., its soluble forms, rescued the mouse phenotype. Interestingly, normal
podocytes adhere to sVEGFR-1/sFlt1-14, but this adhesion is not mediated by integrin binding.
Soluble receptors interact with podocyte membrane in a heparin-dependent way and directly bind
to the glycosphingolipid ganglioside (GM) 3, a component of lipid rafts [90]. As in the case of α5β1
integrin binding, VEGF-A does not mediate sVEGFR-1/sFlt1-14 direct binding to GM3. Upon adhesion
on sVEGFR-1/sFlt1-14, podocytes transduce a signal that comprises phosphorylation of syndecan 1,
syndecan 4, and nephrin, and specifically regulates actin cytoskeleton. These interactions are present
in pericytes and perivascular cells from various tissues, but not in endothelial cells themselves [90].
Altogether, these data indicate that soluble VEGFR-1 isoforms regulate vascular integrity and
movements by binding to molecules different from VEGFs.
7. Conclusions
The role of transmembrane VEGFR-1 in the angiogenic process has been underestimated for
a long period, probably because of its dispensability as tyrosine kinase receptor during embryonic
development. In recent days, transmembrane VEGFR-1 and its selective ligands PlGF and VEGF-B
have been highly involved in pathological angiogenesis where they play non-redundant roles [91,92].
Soluble VEGFR-1 isoforms have been clearly implicated in pathological angiogenesis as well, because
of their action as VEGF-sinks and/or inhibition of transmembrane VEGFR dimerization and signaling.
However, sVEGFR-1/sFlt-1 are likely to have an active role in angiogenesis, which is exerted by binding
molecules different from VEGFs. Perivascular cells produce and bind to soluble VEGFR-1 isoforms
through GM3 ganglioside, thus controlling actin cytoskeleton dynamics [90]. Since destabilization of
pericyte-endothelial interactions is a prerequisite for sprouting angiogenesis and requires alteration of
perivascular cell cytoskeleton, as well as modification of adhesion contacts with basement membrane,
these findings support the hypothesis that sVEGFR-1/sFlt1-14 are involved in vessel sprouting, taking
part in different molecular interactions. Our data indicate that the presence of sVEGFR-1 shifts α5β1
integrin signaling from a classic adhesion pathway to a more dynamic one [86]. Presence of sVEGFR-1
in the endothelial cell microenvironment during vessel sprouting has been clearly shown [55,56],
as well as augmented expression of α5β1 integrin [93]. These data suggest that sVEGFR-1/sFlt1-14
participate in vessel sprouting with mechanisms that go beyond VEGF binding. At present, it is not
possible to dissect the relative importance of VEGFR-1 interactions with VEGFs and α5β1 integrin,
since they are mediated by the same VEGFR-1 D2, even if they involve different amino acid residues.
Development of tailored sVEGFR-1 mutants, able to selectively interact with VEGFs or with α5β1
integrin, is required to clarify this point.
In conclusion, new data are required to understand the balance between sVEGFR-1/sFlt1-14
promoting and inhibiting roles in angiogenesis, and to develop novel and effective therapeutic
compounds targeting these molecules.
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